Novartis Secures Prostate Cancer Treatment With Endocyte Deal
Novartis Oncology

Endocyte Inc. (ECYT) agreed to be acquired by Swiss drugs giant Novartis AG (NVS) for $2.1 billion.

The deal values the developer of cancer treatments at $24 a share, a 54% premium to Endocyte's closing price on Wednesday of $15.56.

Novartis will get its hands on Endocyte's promising Lu-PSMA-617, a radioligand treatment that targets prostate cancer by attaching radioactive Lutetium to cancerous cells.

"The proposed acquisition of Endocyte builds on our growing capability in radio-pharmaceuticals, which is expected to be an increasingly important treatment option for patients and a key growth driver for our business," said Novartis Oncology CEO Liz Barrett in a statement. "We are also excited about the opportunity to break into the prostate cancer arena with a near-term product that has the potential to make a meaningful impact for patients in great need of more options."

Endocyte shares rose more than 50% in premarket trading on Thursday to $23.39.

This story first appeared on TheStreet's sister site, The Deal, on Thursday.

More from Investing

What We Learned from Microsoft, EA, TI and Booking's Earnings Calls

What We Learned from Microsoft, EA, TI and Booking's Earnings Calls

Nvidia Wipes Nearly $25 Billion From Its Market Cap After Earnings Day Disaster

Nvidia Wipes Nearly $25 Billion From Its Market Cap After Earnings Day Disaster

Closed-End Funds Seeing Consolidation

Closed-End Funds Seeing Consolidation

Facebook Stock Slides Another 3% as Woes Continue

Facebook Stock Slides Another 3% as Woes Continue

Chart of the Day: How Jerome Powell Could Shift the Semiconductor Landscape

Chart of the Day: How Jerome Powell Could Shift the Semiconductor Landscape